#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Spina bifida Phaeochromocytoma Central nervous system lymphoma Transient ischaemic attack Gaucher's disease type I Lymphatic malformation Focal segmental glomerulosclerosis Endometrial cancer recurrent Chronic inflammatory demyelinating polyradiculoneuropathy Metachromatic leukodystrophy Noonan syndrome Pemphigus Salivary gland cancer Oropharyngeal cancer recurrent Iron overload More trials…

    Learn about Rare Diseases

    Cholangitis sclerosing Uterine leiomyosarcoma – Life with Disease Breast angiosarcoma – Life with Disease Phenylketonuria – Life with Disease Wiskott-Aldrich syndrome – Basic Information Congenital generalised lipodystrophy Tuberous sclerosis complex – Diagnostics Cystic fibrosis – Treatment Familial haemophagocytic lymphohistiocytosis – Diagnostics Castleman’s disease – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Octocog Alfa Fludrocortisone Water For Injection Censavudine Rbd1016 Sarilumab Melphalan Egl-001 Ecoo18A Ubiquinol Vatiquinone R3R01 Lutropin Alfa Domperidone Zetomipzomib Fazirsiran Apixaban Ucp2 OMEGA-3-ACID ETHYL ESTERS 90 Levamlodipine Succinate More therapies…

    Learn about Your Condition

    Haemorrhage prophylaxis Myotonia Menopause Corticobasal degeneration Pulmonary venous thrombosis Urticaria Mesothelioma malignant Anaemia of pregnancy Tympanic membrane perforation H1N1 influenza Hypogonadism male Oesophageal achalasia Medulloblastoma recurrent Colorectal cancer stage III Myotonic dystrophy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Adenocarcinoma pancreas

  • Safety Study of VCN-01 with nab‑Paclitaxel and Gemcitabine in Newly Diagnosed Metastatic Pancreatic Cancer Patients

    Recruiting

    2 1 1
    Investigated Drugs:
    • Genetically Modified Human Adenovirus Encoding Human Ph20 Hyaluronidase
    Spain

  • A study testing ASP3082 in patients with advanced or spreading non-small cell lung cancer and pancreatic ductal adenocarcinoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Adenocarcinoma pancreas
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Glucose, Anhydrous
    • ASP3082
    France

  • A Study Testing BNT329 Safety and Effectiveness in Patients With Advanced Solid Tumors That Express the CA19-9 Tumor Marker

    Recruiting

    2 1 1
    Investigated Diseases:
    • Adenocarcinoma pancreas
    • Cholangiocarcinoma
    • Colorectal adenocarcinoma
    Germany Spain

  • A Study of Olaparib Maintenance Treatment for Patients with Metastatic Pancreatic Cancer That Responded to First-Line Chemotherapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Adenocarcinoma pancreas
    Investigated Drugs:
    • Olaparib
    Italy

  • A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

    Recruiting

    4 1 1
    Investigated Diseases:
    • Pancreatic carcinoma metastatic
    • Adenocarcinoma pancreas
    Investigated Drugs:
    • 2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE
    • Gemcitabine
    • Paclitaxel Albumin-Bound
    Austria Belgium Czechia Denmark France Germany +9

  • Study of drug combination therapy after surgery in patients with resectable pancreatic ductal adenocarcinoma using lab-grown mini-tumors to guide treatment selection

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Adenocarcinoma pancreas
    Investigated Drugs:
    • Calcium Folinate
    • Capecitabine
    • Fluorouracil
    Germany
1 2 3 … 6
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!